It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

(Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and mAbxience ("mAbxience") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its ...

Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab ...

The partnership between Amneal and mAbxience has previously resulted in the launch of ALYMSYS®, a bevacizumab biosimilar, in 2022. The proposed biosimilars could offer more affordable ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

which has already got a biosimilar to Roche’s Avastin (bevacizumab) cancer drug backed by the FDA. Amgen already has a biosimilar of AbbVie’s Humira (adalimumab) approved in the US ...

and Novartis' Lucentis (ranibizumab), approved biosimilars of those two drugs, and Roche's Vabysmo (faricimab). Compounded bevacizumab formulations are sometimes used to treat wet AMD but ...

Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy and similar safety profiles to those taking the originator product, Avastin ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...